Bennett Jean 4

What Happened

• Bennett Jean, a director of REGENXBIO (RGNX), was granted two awards on May 29, 2026: 9,807 shares (reported as RSU underlying common stock) and a 46,600-share derivative award. Both grants show an acquisition price of $0.00 and therefore have $0 reported cash cost at grant.

Key Details

• Transaction date: 2026-05-29; Form 4 filed: 2026-06-02.
• Awards: 9,807 shares (RSU) and 46,600-share derivative award (both reported at $0.00).
• Vesting: Footnote F1 — the 9,807 RSU shares vest 100% on May 29, 2027, subject to continued service. Footnote F2 — the 46,600-share derivative award will vest on May 29, 2027, subject to continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed June 2, 2026 for the May 29 transaction (within the normal two-business-day reporting window in most cases).

Context

• These are grants/awards (non-cash compensation) to a board member and are commonly part of director pay; they do not represent a cash purchase or sale. Because both awards vest one year after grant, the insider does not immediately receive freely transferable shares. Grants provide limited direct signal about immediate insider trading sentiment.